Neurocrine Biosciences Inc vs Redwire Corporation — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Redwire Corporation trades at $9.7 (market cap $2.05B). The key difference: Neurocrine Biosciences Inc is far larger — about 8.5× Redwire Corporation's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals.
| NBIX | RDW | |
|---|---|---|
Market Cap | $17.40B | $2.05B |
Sector | Health | Technology |
52-Week High | $180.55 | $25.90 |
52-Week Low | $123.10 | $5.06 |
Enterprise Value | $16.49B | $2.12B |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →